DSRV.io · Enforcement-informed quality intelligence
DSRVDSRV.io
Browse by regulation3 articles · 3 moderate

ICH Q1A(R2)

Every DSRV article whose Regulatory Snapshot cites ICH Q1A(R2): the enforcement case behind it, the inspection exposure it created, and what the desk would do about it.

Inspection exposure across the set
In brief
What has FDA cited under ICH Q1A(R2)?
3 DSRV articles cite ICH Q1A(R2). Enforcement cases behind them: ICH Q1A(R2) stability data expectations and FDA review practice for retest period and shelf-life justifications under 21 CFR Part 211; Recurring FDA stability program observations under 21 CFR §211.166 and excursion-handling expectations informed by ICH Q1A(R2); FDA draft guidance for industry, Q1 Stability Testing of Drug Substances and Drug Products, published for U.S. comment in June 2025 under Docket FDA-2025-D-1106, consolidating the ICH Q1A-F and Q5C stability guidelines. Inspection exposure across them: 3 moderate.
What does DSRV recommend for ICH Q1A(R2)?
From the newest article (What Evidence Supports a Stability Justification?): A shelf-life justification is an evidence argument - long-term data, demonstrated stability-indicating methods, and trend analysis, not a stack of individually passing results. DSRV is decision support, not legal advice; verify against the official source each article names.
  1. 8 min readModerate exposure

    What Evidence Supports a Stability Justification?

    A shelf-life claim is only as strong as the stability evidence behind it. We outline what ICH Q1A(R2)-aligned data, trend analysis, and supporting studies actually substantiate a justification.

    Case
    ICH Q1A(R2) stability data expectations and FDA review practice for retest period and shelf-life justifications under 21 CFR Part 211.
    DSRV take
    A shelf-life justification is an evidence argument - long-term data, demonstrated stability-indicating methods, and trend analysis, not a stack of individually passing results.
  2. 7 min readModerate exposurecited as a tag

    When Stability Data Gaps Become Inspection Exposure

    Not every stability gap is equal. A missing time point, an unmanaged excursion, or an under-powered trend can quietly become an inspection finding. Here is how to triage which gaps create real exposure.

    Case
    Recurring FDA stability program observations under 21 CFR §211.166 and excursion-handling expectations informed by ICH Q1A(R2).
    DSRV take
    The inspection question is never whether gaps exist - it is whether each gap weakens the shelf-life justification and whether you documented how you managed it.
  3. 5 min readModerate exposurecited as a tag

    Your Stability Program Was Built for a Guideline Stack FDA Is Replacing

    FDA's June 2025 draft ICH Q1 guidance consolidates the Q1A-F and Q5C stability guideline stack. It is still draft and not for implementation, but it signals where global stability expectations are moving.

    Case
    FDA draft guidance for industry, Q1 Stability Testing of Drug Substances and Drug Products, published for U.S. comment in June 2025 under Docket FDA-2025-D-1106, consolidating the ICH Q1A-F and Q5C stability guidelines.
    DSRV take
    The right response to a draft-not-for-implementation label is a controlled gap assessment against Sections 3, 7, 13, and 15, not blind SOP revision, because teams that map the direction of travel early avoid retrofitting under pressure at final regional implementation.
Address this risk

Pressure-test your evidence before an inspector reads it

Bring the document that has to hold up under ICH Q1A(R2). DSRV maps the evidence, names the gaps, and routes judgment calls to human review. Controlled intake, no public file upload.

Apply for the Stability Pilot Ask The Vault about ICH Q1A(R2)

Regulatory intelligence and interpretation, not legal advice. Verify against the official FDA or ICH source each article names.